EYP-1901 for Retinal Exudative Diseases - Scorecard - MDSpire

EYP-1901 for Retinal Exudative Diseases

An overview of the current status of the EYP-1901 clinical trial program in wet AMD and DME, presented at Hawaiian Eye and Retina 2026

  • By

  • Sumit Sharma

  • January 23, 2026

  • 5 min

Share

Clinical Scorecard: EYP-1901 for Retinal Exudative Diseases

At a Glance

CategoryDetail
Condition
Key MechanismsInhibition of VEGFRs, PDGFR, and IL-6 signaling; sustained release of vorolanib via Durasert E™ technology.
Target Population
Care Setting

Key Highlights

  • EYP-1901 provides sustained drug delivery over at least 6 months with specific trial data supporting treatment burden reduction.

Guideline-Based Recommendations

Diagnosis

    Management

    • Consider EYP-1901 as a treatment option for patients with high treatment burden, particularly those with specific visual acuity thresholds.

    Monitoring & Follow-up

      Risks

        Patient & Prescribing Data

        EYP-1901 shows promise in reducing treatment frequency and improving outcomes, with metrics from clinical trials.

        Clinical Best Practices

        • Utilize a multi-mechanism approach in treatment planning, incorporating examples of combination therapies.

        References

        Original Source(s)

        EYP-1901 for Retinal Exudative Diseases

        • by Sumit Sharma

        • January 23, 2026

        Related Content

        Pediatric Case Study of Ocular Loiasis Without Microfilaremia

        Clinical Progression Scale-Pediatrics: A Potential Metric of Respiratory Syncytial Virus Severity and Progression in Children

        AI Falls Short on Differential Dx

        New PrIME-LLM benchmark shows strong diagnostic accuracy but persistent gaps in clinical reasoning across 21 large language models